Monte Research Development vs Selling General Administrative Analysis

GLUE Stock

USD 8.35 0.01 0.12%

Monte Rosa financial indicator trend analysis is infinitely more than just investigating Monte Rosa Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Monte Rosa Therapeutics is a good investment. Please check the relationship between Monte Rosa Research Development and its Selling General Administrative accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

Research Development vs Selling General Administrative

Research Development vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Monte Rosa Therapeutics Research Development account and Selling General Administrative. At this time, the significance of the direction appears to have totally related.

The correlation between Monte Rosa's Research Development and Selling General Administrative is 1.0. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Monte Rosa Therapeutics, assuming nothing else is changed. The correlation between historical values of Monte Rosa's Research Development and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Monte Rosa Therapeutics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Research Development i.e., Monte Rosa's Research Development and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

1.0

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Research Development

Selling General Administrative

Most indicators from Monte Rosa's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

As of November 22, 2024, Selling General Administrative is expected to decline to about 17.5 M. In addition to that, Tax Provision is expected to decline to about 185.9 K

	2021	2022	2023	2024 (projected)
Interest Expense	1.1M	3.8M	4.3M	4.5M
Depreciation And Amortization	2.1M	8.6M	6.2M	3.9M

Interest Expense Depreciation And Amortization

Monte Rosa fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		0.76	0.63	0.75	0.97	0.97	0.83	-0.69	-0.83	0.84	0.81	0.85	0.99	0.8	-0.85	0.8	0.39	0.98	0.99	0.55	0.97	0.8	-0.45	0.99	-0.85	0.99
Short Long Term Debt Total	0.76		0.98	0.88	0.64	0.68	0.64	-0.41	-0.7	0.88	0.63	0.67	0.76	0.52	-0.98	0.64	0.71	0.81	0.71	0.8	0.64	0.65	-0.43	0.76	-0.98	0.71
Other Current Liab	0.63	0.98		0.85	0.48	0.54	0.55	-0.28	-0.62	0.82	0.5	0.57	0.62	0.38	-0.94	0.55	0.76	0.69	0.58	0.82	0.48	0.57	-0.4	0.62	-0.94	0.56
Total Current Liabilities	0.75	0.88	0.85		0.58	0.72	0.84	-0.28	-0.87	0.99	0.49	0.85	0.71	0.31	-0.9	0.83	0.89	0.72	0.79	0.96	0.58	0.83	-0.6	0.71	-0.9	0.65
Total Stockholder Equity	0.97	0.64	0.48	0.58		0.95	0.72	-0.78	-0.72	0.7	0.85	0.75	0.98	0.87	-0.74	0.7	0.17	0.96	0.94	0.34	1.0	0.69	-0.36	0.98	-0.74	0.99
Net Tangible Assets	0.97	0.68	0.54	0.72	0.95		0.8	-0.71	-0.89	0.82	0.81	0.83	0.96	0.67	-0.79	0.89	0.35	0.92	0.97	0.51	0.95	0.85	-0.63	0.96	-0.79	0.95
Property Plant And Equipment Net	0.83	0.64	0.55	0.84	0.72	0.8		-0.21	-0.9	0.88	0.38	1.0	0.76	0.5	-0.73	0.84	0.68	0.78	0.89	0.76	0.72	0.92	-0.52	0.77	-0.73	0.73
Net Debt	-0.69	-0.41	-0.28	-0.28	-0.78	-0.71	-0.21		0.36	-0.38	-0.97	-0.25	-0.77	-0.65	0.49	-0.42	0.19	-0.66	-0.63	0.01	-0.78	-0.26	0.2	-0.76	0.49	-0.79
Retained Earnings	-0.83	-0.7	-0.62	-0.87	-0.72	-0.89	-0.9	0.36		-0.92	-0.53	-0.91	-0.78	-0.35	0.8	-0.99	-0.68	-0.77	-0.88	-0.78	-0.72	-0.99	0.82	-0.79	0.8	-0.74
Accounts Payable	0.84	0.88	0.82	0.99	0.7	0.82	0.88	-0.38	-0.92		0.59	0.89	0.81	0.42	-0.92	0.88	0.81	0.8	0.87	0.9	0.7	0.87	-0.61	0.81	-0.92	0.75
Cash	0.81	0.63	0.5	0.49	0.85	0.81	0.38	-0.97	-0.53	0.59		0.42	0.87	0.68	-0.69	0.56	0.05	0.79	0.75	0.23	0.85	0.42	-0.32	0.86	-0.69	0.87
Non Current Assets Total	0.85	0.67	0.57	0.85	0.75	0.83	1.0	-0.25	-0.91	0.89	0.42		0.79	0.53	-0.75	0.85	0.67	0.81	0.91	0.76	0.75	0.92	-0.52	0.8	-0.75	0.76
Cash And Short Term Investments	0.99	0.76	0.62	0.71	0.98	0.96	0.76	-0.77	-0.78	0.81	0.87	0.79		0.82	-0.84	0.76	0.32	0.98	0.97	0.48	0.98	0.74	-0.43	1.0	-0.84	1.0
Net Receivables	0.8	0.52	0.38	0.31	0.87	0.67	0.5	-0.65	-0.35	0.42	0.68	0.53	0.82		-0.57	0.29	-0.06	0.85	0.72	0.09	0.87	0.36	0.09	0.82	-0.57	0.85
Common Stock Total Equity	-0.85	-0.98	-0.94	-0.9	-0.74	-0.79	-0.73	0.49	0.8	-0.92	-0.69	-0.75	-0.84	-0.57		-0.74	-0.69	-0.88	-0.81	-0.79	-0.74	-0.75	0.52	-0.84	1.0	-0.8
Common Stock Shares Outstanding	0.8	0.64	0.55	0.83	0.7	0.89	0.84	-0.42	-0.99	0.88	0.56	0.85	0.76	0.29	-0.74		0.62	0.72	0.85	0.72	0.7	0.96	-0.87	0.76	-0.74	0.72
Non Current Liabilities Total	0.39	0.71	0.76	0.89	0.17	0.35	0.68	0.19	-0.68	0.81	0.05	0.67	0.32	-0.06	-0.69	0.62		0.37	0.45	0.98	0.17	0.67	-0.51	0.32	-0.69	0.24
Other Current Assets	0.98	0.81	0.69	0.72	0.96	0.92	0.78	-0.66	-0.77	0.8	0.79	0.81	0.98	0.85	-0.88	0.72	0.37		0.94	0.52	0.96	0.75	-0.39	0.98	-0.88	0.97
Other Stockholder Equity	0.99	0.71	0.58	0.79	0.94	0.97	0.89	-0.63	-0.88	0.87	0.75	0.91	0.97	0.72	-0.81	0.85	0.45	0.94		0.6	0.94	0.85	-0.5	0.97	-0.81	0.95
Total Liab	0.55	0.8	0.82	0.96	0.34	0.51	0.76	0.01	-0.78	0.9	0.23	0.76	0.48	0.09	-0.79	0.72	0.98	0.52	0.6		0.34	0.76	-0.56	0.48	-0.79	0.41
Net Invested Capital	0.97	0.64	0.48	0.58	1.0	0.95	0.72	-0.78	-0.72	0.7	0.85	0.75	0.98	0.87	-0.74	0.7	0.17	0.96	0.94	0.34		0.69	-0.35	0.98	-0.74	0.99
Property Plant And Equipment Gross	0.8	0.65	0.57	0.83	0.69	0.85	0.92	-0.26	-0.99	0.87	0.42	0.92	0.74	0.36	-0.75	0.96	0.67	0.75	0.85	0.76	0.69		-0.8	0.75	-0.75	0.71
Short Long Term Debt	-0.45	-0.43	-0.4	-0.6	-0.36	-0.63	-0.52	0.2	0.82	-0.61	-0.32	-0.52	-0.43	0.09	0.52	-0.87	-0.51	-0.39	-0.5	-0.56	-0.35	-0.8		-0.42	0.52	-0.39
Total Current Assets	0.99	0.76	0.62	0.71	0.98	0.96	0.77	-0.76	-0.79	0.81	0.86	0.8	1.0	0.82	-0.84	0.76	0.32	0.98	0.97	0.48	0.98	0.75	-0.42		-0.84	1.0
Capital Stock	-0.85	-0.98	-0.94	-0.9	-0.74	-0.79	-0.73	0.49	0.8	-0.92	-0.69	-0.75	-0.84	-0.57	1.0	-0.74	-0.69	-0.88	-0.81	-0.79	-0.74	-0.75	0.52	-0.84		-0.8
Net Working Capital	0.99	0.71	0.56	0.65	0.99	0.95	0.73	-0.79	-0.74	0.75	0.87	0.76	1.0	0.85	-0.8	0.72	0.24	0.97	0.95	0.41	0.99	0.71	-0.39	1.0	-0.8

Click cells to compare fundamentals

Monte Rosa Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:

How To Invest In Monte

Details

Is Monte Stock a good investment?

Details

What is Monte Rosa's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.78)

Revenue Per Share

0.221

Return On Assets

(0.28)

Return On Equity

(0.61)

The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Monte Research Development vs Selling General Administrative Analysis

Research Development vs Selling General Administrative

Research Development vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Research Development

Selling General Administrative

Monte Rosa fundamental ratios Correlations

Monte Rosa Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Working Capital	+ 1.0	Cash And Short Term Investments
Capital Stock	+ 1.0	Common Stock Total Equity
Net Working Capital	+ 1.0	Total Current Assets

Property Plant And Equipment Gross	- 0.99	Retained Earnings
Common Stock Shares Outstanding	- 0.99	Retained Earnings
Capital Stock	- 0.98	Short Long Term Debt Total
Common Stock Total Equity	- 0.98	Short Long Term Debt Total
Cash	- 0.97	Net Debt
Capital Stock	- 0.94	Other Current Liab